Invited Speakers

The University of Auckland

Read More

Ian Reid is an endocrinologist and Distinguished Professor at the University of Auckland.  His research interests include calcium metabolism, vitamin D, osteoporosis and Paget’s disease. He has written extensively about the safety and efficacy of calcium supplements, how to define vitamin D deficiency, and has been involved in development of most new osteoporosis treatments in the last 30 years, particularly the bisphosphonates. He is a past-president of the International Bone and Mineral Society (IBMS), and recipient of research awards from the Australian & New Zealand Bone & Mineral Society, the European Calcified Tissue Society, the American Society of Bone and Mineral Research, and the New Zealand Prime Minister’s Science Prize. 

Westmead Hospital

Read More

Shejil is an Endocrinology staff specialist at Westmead Hospital and is undergoing a PhD at the University of Sydney based at Royal North Shore and Westmead Hospital, Sydney. He is running the ROLEX-DUO clinical trial combining romosozumab with high intensity resistance exercise in postmenopausal osteoporosis. He has academic interests in sequential and combination osteoanabolic treatments and denosumab rebound. He is also passionate about promoting career and professional development for early career clinicians and scientists through his current roles as Co-Chair of the ANZBMS ECIC, Co-Convenor of the ESA Clinical Weekend and host of the ESA Hormone Hotseat podcast.

St Vincent’s Hospital

Read more

Dr Jennifer Snaith is clinical researcher and Staff Specialist endocrinologist who leads the Diabetes in Youth service at St Vincent’s Hospital, Sydney. Her research interest is the intersection between type 1 diabetes, metabolic and cardiovascular health, and the role of adjunctive therapies in type 1 diabetes. She was awarded the UNSW Dean’s Award for her PhD, a study of the effect of metformin on muscle and liver insulin resistance in type 1 diabetes, assessed using hyperinsulinaemic-euglycaemic clamps. She conducts adjunctive therapies clinical trials in type 1 diabetes through the Garvan Institute of Medical Research and the Victor Chang Cardiac Research Institute. Active or completed trials include the INTIMET study (metformin), RESET1 (semaglutide), TIRTLE1 (tirzepatide) and TIRTLE2 (tirzepatide). Jen’s post-doctoral work is a supported by Breakthrough T1D Australia.